Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 5/20 | 0.56 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.38 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.38 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.36 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.36 |
| ▸ | ALB | P02768 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.36 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.36 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.36 |
| ▸ | EP300 | Q09472 | 8/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14948806 | 1.00 | FGFR1 (0.56) | FGFR1SLC22A6LMNATHRBMTOR | |
| SCHEMBL16197895 | 0.86 | FGFR1 (0.48) | FGFR1SLC22A6LMNATHRBMTOR | |
| SCHEMBL24420265 | 0.86 | FGFR1 (0.48) | FGFR1SLC22A6LMNATHRBMTOR | |
| SCHEMBL24420129 | 0.86 | FGFR1 (0.48) | FGFR1SLC22A6LMNATHRBMTOR | |
| SCHEMBL7269771 | 0.84 | FGFR1 (0.52) | FGFR1SLC22A6LMNATHRBMTOR | |
| SCHEMBL7269776 | 0.84 | FGFR1 (0.52) | FGFR1SLC22A6LMNATHRBMTOR | |
| SCHEMBL16038518 | 0.84 | FGFR1 (0.53) | FGFR1SLC22A6LMNATHRBMTOR | |
| SCHEMBL16039335 | 0.84 | FGFR1 (0.53) | FGFR1SLC22A6LMNATHRBMTOR | |
| SCHEMBL12652844 | 0.83 | FGFR1 (0.51) | FGFR1SLC22A6LMNATHRBMTOR | |
| SCHEMBL24420123 | 0.83 | FGFR1 (0.58) | FGFR1SLC22A6LMNATHRBMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165295-A1 | Compounds, Compositions and Methods for Treating Ocular Conditions | CHIMERIX, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120010170-A1 | \"Methods of Reducing Nephrotoxicity in Subjects Administered Nucleoside Phosphonates\ | EMERGENT BIODEFENSE OPERATIONS LANSING LLC | 2012-01-12 | — | — | US | disclosed |
| US-7994143-B2 | Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates | CHIMERIX, INC. (US) | 2011-08-09 | — | — | US | disclosed |
| WO-2011053812-A1 | METHODS OF TREATING VIRAL ASSOCIATED DISEASES | CHIMERIX, INC. (US) | 2011-05-05 | — | — | WO | disclosed |
| WO-2011011519-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OCULAR CONDITIONS | CHIMERIX, INC. (US) | 2011-01-27 | — | — | WO | disclosed |
| US-20100249056-A1 | Metabolically Stable Alkoxyalkyl Esters of Antiviral or Antiproliferative Phosphonates, Nucleoside Phosphonates and Nucleoside Phosphates | CHIMERIX, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-7749983-B2 | Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates | CHIMERIX, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| WO-2008133966-A1 | METHODS OF REDUCING NEPHROTOXICITY IN SUBJECTS ADMINISTERED WITH NUCLEOSIDE | CHIMERIX, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010170-A1 | \"Methods of Reducing Nephrotoxicity in Subjects Administered Nucleoside Phosphonates\ | CSGALNACT1, SLC28A1, SLC10A1 | FGFR1 3225/4885SLC22A6 401/4885LMNA 1394/4885 |
| US-20120165295-A1 | Compounds, Compositions and Methods for Treating Ocular Conditions | EYA3, EYA2, PDE6C | FGFR1 1923/4885SLC22A6 2635/4885LMNA 2085/4885 |
| US-20100249056-A1 | Metabolically Stable Alkoxyalkyl Esters of Antiviral or Antiproliferative Phosphonates, Nucleoside Phosphonates and Nucleoside Phosphates | PNP, TYMP, ENPP1 | FGFR1 1036/4885SLC22A6 1414/4885LMNA 3293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.